| 宋林川,都兴隆,卢宇博,金诗洋,李咸君,单 明,张国强.新辅助化疗后腋窝病理完全缓解乳腺癌的预后分析[J].现代生物医学进展英文版,2021,(19):3796-3800. |
| 新辅助化疗后腋窝病理完全缓解乳腺癌的预后分析 |
| Prognosis of Aortic Pathology and Its Influencing Factors after Neoadjuvant Chemotherapy in Patients with Breast Cancer |
| Received:November 27, 2020 Revised:December 25, 2020 |
| DOI：10.13241/j.cnki.pmb.2021.19.041 |
| 中文关键词: 乳腺癌 新辅助化疗 腋窝淋巴结 病理完全缓解 生存预后 |
| 英文关键词: Breast cancer Neoadjuvant chemotherapy Axillary lymph node Complete pathological respond Survival prognosis |
| 基金项目:黑龙江省自然科学基金面上项目（H201333）；黑龙江省青年科学基金项目（QC2015113）；黑龙江省博士后基金项目（LBH-Z16120） |
|
| Hits: 710 |
| Download times: 540 |
| 中文摘要: |
| 摘要 目的：研究乳腺癌患者新辅助化疗（NAC）后达到腋窝淋巴结病理完全缓解（pathologic complete response of axillary，apCR）的远期生存以及影响远期生存的相关因素分析。方法：回顾性分析哈尔滨医科大学附属肿瘤医院乳腺外科624例乳腺癌患者的住院资料，采用Kaplan-Meier生存分析以及COX回归分析的统计学分析方法，分析乳腺癌患者新辅助化疗后腋窝状态与无病生存（DFS）和总生存（OS）的关系及影响apCR预后的因素。结果：apCR与非apCR患者比较DFS（P=0.013）和OS（P=0.037）差异具有统计学意义，apCR患者的预后与年龄、肿瘤大小、肿瘤受体状态、HER-2、ki67状态、分子分型等因素无相关性。结论：与非apCR患者相比，乳腺癌患者新辅助化疗后apCR患者预后更好，但apCR患者预后良好的因素仍需进一步临床试验分析。 |
| 英文摘要: |
| ABSTRACT Objective: To study the long-term survival of pathologic complete response of axillary (apCR) and related factors affecting long-term survival after neoadjuvant chemotherapy (NAC) in breast cancer patients. Methods: Retrospective analysis of 624 cases of breast cancer patients with breast surgery in the Affiliated Tumor Hospital of Harbin Medical University, Kaplan-Meier survival analysis and statistical analysis of COX regression analysis, analysis of axillary status and disease-free survival after neoadjuvant chemotherapy in breast cancer patients The relationship between (DFS) and overall survival (OS) and factors affecting the prognosis of apCR. Results: The difference in DFS (P=0.013) and OS (P=0.037) was statistically significant between apCR and non-apCR patients. Prognosis and age, tumor size, tumor receptor status, HER-2, ki67 status, molecular typing in apCR patients Other factors are not relevant. Conclusion: Compared with non-apCR patients, the prognosis of apCR patients after breast cancer patients with neoadjuvant chemotherapy is better, but the prognosis of apCR patients still needs further clinical trial analysis. |
|
View Full Text
View/Add Comment Download reader |
| Close |
